You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA216
  • Published:  23 February 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Research recommendations coming out of this guidance

  • Research should be carried out to compare the clinical effectiveness of bendamustine with chlorambucil at the higher dose used in the Chronic Lymphocytic Leukaemia Trial 4 (CLL4).

Back to top